CAL
RARE icon

Capital Advisors Ltd’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital Advisors Ltd’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed – – 1558
2022
Q3 		$0 Sell
3
-2
-40% -$103 ﹤0.01% 1468
2022
Q2 		$0 Buy
+5
New +$308 ﹤0.01% 1264
2022
Q1 		– Sell
-2
Closed – – 1158
2021
Q4 		$0 Buy
+2
New +$163 ﹤0.01% 913

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Capital Advisors Ltd's RARE Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 3 shares.

Capital Advisors Ltd first reported a position in RARE in Q4 2021 and held it in 3 quarters. The position peaked at $0 in Q3 2022. 227 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

  • Capital Advisors Ltd reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 3 Ultragenyx Pharmaceutical shares in Q4 2022.
  • Capital Advisors Ltd first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and held it in 3 quarters.
  • Capital Advisors Ltd's Ultragenyx Pharmaceutical position peaked at $0 in Q3 2022.
  • 227 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.